PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer"
DOI: 10.1186/s12943-017-0660-5
Abstract: BackgroundThe MET receptor tyrosine kinase represents a promising target in cancer. PIK3CA activating mutations are common in several tumor types and can potentially confer resistance to anti-receptor tyrosine kinase therapy.MethodsMET and/or PI3K pathway inhibition was… read more here.
Keywords: met driven; met inhibition; inhibition; resistance ... See more keywords